Pergi ke luar talian dengan aplikasi Player FM !
LIVE FROM EHA 2024 - Sonrotoclax plus Zanubrutinib in R/R CLL
Manage episode 424763736 series 2812899
In this episode of our podcast, recorded at the European Hematology Association (EHA) meeting in Madrid, Spain, we discuss updated results of the BGB-11417-101 trial with Dr. Stephen Opat. The BGB-11417-101 trial examined the efficacy and safety of sonrotoclax plus zanubrutinib for the treatment of R/R CLL.
Our Guest:
Dr. Stephen Opat is the director of Clinical Haematology at Monash Health, founder and chair of the Australasian Lymphoma and Related Diseases Registry and lead investigator of the Melbourne Genomics Health Alliance Lymphoma Flagship.
This podcast episode was sponsored by BeiGene Canada ULC.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
67 episod
Manage episode 424763736 series 2812899
In this episode of our podcast, recorded at the European Hematology Association (EHA) meeting in Madrid, Spain, we discuss updated results of the BGB-11417-101 trial with Dr. Stephen Opat. The BGB-11417-101 trial examined the efficacy and safety of sonrotoclax plus zanubrutinib for the treatment of R/R CLL.
Our Guest:
Dr. Stephen Opat is the director of Clinical Haematology at Monash Health, founder and chair of the Australasian Lymphoma and Related Diseases Registry and lead investigator of the Melbourne Genomics Health Alliance Lymphoma Flagship.
This podcast episode was sponsored by BeiGene Canada ULC.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
67 episod
सभी एपिसोड
×Selamat datang ke Player FM
Player FM mengimbas laman-laman web bagi podcast berkualiti tinggi untuk anda nikmati sekarang. Ia merupakan aplikasi podcast terbaik dan berfungsi untuk Android, iPhone, dan web. Daftar untuk melaraskan langganan merentasi peranti.